亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Antimicrobial, Stimuli-responsive Polysaccharide

技術優勢
Reduced toxicity and similar efficacy in reducing bacterial growth compared to native chitosanCan be selectively returned to native chitosan at low pH to target specific areas
技術應用
· Broad spectrum nanoantibiotics
詳細技術說明
State of the art antimicrobials have up to 14 years of efficacy before resistance develops in microbes, after which a new antimicrobial compound must be researched and developed. The process can take years and millions of dollars, which has led many pharmaceutical companies to reduce investment in new antibiotics. Nanoantibiotics have recently gained attention as a therapeutic strategy. They are nanomaterials that have inherent antimicrobial activity or improve efficacy and safety of antibiotics administration. Nanoantibiotics have different attack mechanisms that result in advantages over conventional antibiotics. Chitosan is a natural material derived from the shells of shrimp and other crustaceans which have shown promise as a nanoantibiotic. However, native chitosan has low solubility at biological pH and therefore low therapeutic potential against the microbes. UCI researchers have developed a way to make acid-transforming chitosan (ATC) to enhance solubility and lower toxicity, while sustaining the bioactivity. The researchers believe that the method can create a chitosan that targets various locations in the body.
*Abstract

State of the art antimicrobial therapeutics, while effective and promising, remain only short-term solutions to the overall challenge of drug-resistant microbes. UCI researchers have developed a chitosan-based nanoantibiotic that is non-toxic and carries potential for broad spectrum use.

*Principal Investigation

Name: Julius Edson

Department:


Name: Young Jik Kwon

Department:

其他

State Of Development

Various formulations have been made and in vitro and in vivo studies have been performed to understand the appropriate pharmacological doses.


Tech ID/UC Case

28937/2018-062-0


Related Cases

2018-062-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備